anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In every patient, each one of the two scars, or the other side of a large scar will be assigned to intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. Patients will receive 5 treatment sessions 4 weeks apart.
In this single-blinded prospective randomized study, 10 participants (adults above 18years) with chronic spinal cord injury already managed with active rehabilitation and continuous pelvic nerves stimulation (low-frequency, antidormic) will be randomly assigned in a 1:1 ratio to active taVNS (twice daily, 30 minutes each time), or control with daily sessions of sham taVNS (0.0 mA). Rehabilitation is performed unspecifically by home-rehabilitation's team or physiotherapeutists with exercises adjusted to the participant's functional level. This protocol comprised 15 to 20 weekly hours of multidisciplinary care, including neurofunctional physiotherapy and aquatic therapy, cardiorespiratory physiotherapy (two hours/week). All participants have undergone previously an implantation of a stimulator for chronic neuromodulation of the pelvic somatic nerves according with the LION procedure. Participants and therapeutists will maintain blinding until the completion of the study (6 months). Assessment of gait function, motor symptoms are performed three time, at baseline, at 3-months follow up and at 6months follow up.
There is an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) in patients with inflammatory rheumatic diseases (IRD) including rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, and systemic sclerosis. The mechanism for the development of ASCVD in these conditions has been linked not only to a higher prevalence and undertreatment of traditional cardiovascular (CV) risk factors but importantly to chronic inflammation and a dysregulated immune system which contribute to impaired endothelial and microvascular function, factors that may contribute to accelerated atherosclerosis. Accurate ASCVD risk stratification and optimal risk management remain challenging in this population with many barriers that include lack of validated risk calculators, the remitting and relapsing nature of underlying disease, deleterious effect of medications used to manage rheumatic diseases, multimorbidity, decreased mobility due to joint pain, and lack of clarity about who bears the responsibility of performing CV risk assessment and management (rheumatologist vs. primary care provider vs. cardiologist). Despite recent advances in this field, there remain significant gaps in knowledge regarding the best diagnostic and management approach. The evolving field of Cardio-Rheumatology focuses on optimization of cardiovascular care and research in this patient population through collaboration and coordination of care between rheumatologists, cardiologists, radiologists, and primary care providers. This review aims to provide an overview of current state of knowledge about ASCVD risk stratification in patients with IRD, contributing factors including effect of medications, and review of the current recommendations for cardiovascular risk management in patients with inflammatory disease with a focus on hypertension as a key risk factor.
BACKGROUND: Exosome therapy shows potential for cardiac repair after injury. However, intrinsic challenges such as short half-life and lack of clear targets hinder the clinical feasibility. Here, we report a noninvasive and repeatable method for exosome delivery through inhalation after myocardial infarction (MI), which we called stem cell-derived exosome nebulization therapy (SCENT).
METHODS: Stem cell-derived exosomes were characterized for size distribution and surface markers. C57BL/6 mice with MI model received exosome inhalation treatment through a nebulizer for 7 consecutive days. Echocardiographies were performed to monitor cardiac function after SCENT, and histological analysis helped with the investigation of myocardial repair. Single-cell RNA sequencing of the whole heart was performed to explore the mechanism of action by SCENT. Last, the feasibility, efficacy, and general safety of SCENT were demonstrated in a swine model of MI, facilitated by 3-dimensional cardiac magnetic resonance imaging.
RESULTS: Recruitment of exosomes to the ischemic heart after SCENT was detected by ex vivo IVIS imaging and fluorescence microscopy. In a mouse model of MI, SCENT ameliorated cardiac repair by improving left ventricular function, reducing fibrotic tissue, and promoting cardiomyocyte proliferation. Mechanistic studies using single-cell RNA sequencing of mouse heart after SCENT revealed a downregulation of Cd36 in endothelial cells (ECs). In an EC-Cd36fl/- conditional knockout mouse model, the inhibition of CD36, a fatty acid transporter in ECs, led to a compensatory increase in glucose utilization in the heart and higher ATP generation, which enhanced cardiac contractility. In pigs, cardiac magnetic resonance imaging showed an enhanced ejection fraction (Δ=11.66±5.12%) and fractional shortening (Δ=5.72±2.29%) at day 28 after MI by SCENT treatment compared with controls, along with reduced infarct size and thickened ventricular wall.
CONCLUSIONS: In both rodent and swine models, our data proved the feasibility, efficacy, and general safety of SCENT treatment against acute MI injury, laying the groundwork for clinical investigation. Moreover, the EC-Cd36fl/- mouse model provides the first in vivo evidence showing that conditional EC-CD36 knockout can ameliorate cardiac injury. Our study introduces a noninvasive treatment option for heart disease and identifies new potential therapeutic targets.
OCREVUS can cause infusion reactions, which can include pruritus, rash, urticaria, erythema, bronchospasm, throat irritation, oropharyngeal pain, dyspnea, pharyngeal or laryngeal edema, flushing, hypotension, pyrexia, fatigue, headache, dizziness, nausea, tachycardia, and anaphylaxis. In multiple sclerosis (MS) clinical trials, the incidence of infusion reactions in OCREVUS-treated patients [who received methylprednisolone (or an equivalent steroid) and possibly other pre-medication to reduce the risk of infusion reactions prior to each infusion] was 34 to 40%, with the highest incidence with the first infusion. There were no fatal infusion reactions, but 0.3% of OCREVUS-treated MS patients experienced infusion reactions that were serious, some requiring hospitalization.

Observe patients treated with OCREVUS for infusion reactions during the infusion and for at least one hour after completion of the infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. 

Reducing the Risk of Infusion Reactions and Managing Infusion Reactions 

Administer pre-medication (e.g., methylprednisolone or an equivalent corticosteroid, and an antihistamine) to reduce the frequency and severity of infusion reactions. The addition of an antipyretic (e.g., acetaminophen) may also be considered [see Dosage and Administration (2.2)].

Management recommendations for infusion reactions depend on the type and severity of the reaction [see Dosage and Administration (2.5)]. For life-threatening infusion reactions, immediately and permanently stop OCREVUS and administer appropriate supportive treatment. For less severe infusion reactions, management may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.
The most common adverse reactions with zonisamide (an incidence at least 4% greater than placebo) in controlled clinical trials and shown in descending order of frequency were somnolence, anorexia, dizziness, ataxia, agitation/irritability, and difficulty with memory and/or concentration.

In controlled clinical trials, 12% of patients receiving zonisamide as adjunctive therapy discontinued due to an adverse reaction compared to 6% receiving placebo. Approximately 21% of the 1,336 patients with epilepsy who received zonisamide in clinical studies discontinued treatment because of an adverse reaction. The most common adverse reactions leading to discontinuation were somnolence, fatigue and/or ataxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%). Many of these adverse reactions were dose-related (see WARNINGS and  PRECAUTIONS). 

Adverse Reaction Incidence in Controlled Clinical Trials

Table 4 lists adverse reactions that occurred in at least 2% of patients treated with zonisamide in controlled clinical trials that were numerically more common in the zonisamide group. In these studies, either zonisamide or placebo was added to the patient's current AED therapy.
Ten (10) subjects previously diagnosed and chronically treated for primary hypoparathyroidism will be enrolled. The daily CCS intake will be gradually replaced by reduced amount of elemental calcium from ACC. Five (5) subjects will consume the ACC before having a meal and the other five (5) subjects will consume the ACC after having a meal. The safety and the efficacy of the treatment will be closely monitored throughout this phase.
The present invention relates to a formulation for producing a product to be used to prevent infections by coronavirus, especially SARS-CoV-2, with the aim of reducing the viral load in persons who have tested positive, have symptoms or are asymptomatic. The formulation contains a mixture of components with, in a volume q.s. for 100 of a purified water base, the addition of: 0.2%  chlorhexidine digluconate  (chlorhexidine); 0.2% liquid mint aroma ( AROMAX MENTA LÍQUIDO ); 0.1% Nipazol; 0.1% Nipagin; and 0.1% crystal BHT ( butylhydroxytoluene ). The product is mixed in a conventional mixing device. The resulting product is a liquid, in the form of a mouthwash, for use in particular by persons who are healthy or infected with coronavirus, especially the SARS-CoV-2 strain. The product is used by rinsing the mouth and gargling with 10 ml of the product, a full rinse lasting 30 seconds and being carried out twice daily, resulting in a decrease in the viral load in the saliva of persons diagnosed with Covid-19 and forming a long-lasting protective layer in the region of the oral cavity, oropharynx and epiglottis, inactivating the virus. In the case of persons who are not infected, this layer protects the region the virus first attaches to, thereby preventing potential infection.
Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about an emotionally neutral topic.
Xining is located at the eastern edge of the Qinghai-Tibet Plateau, with an average altitude of >7000 feet (>2000 m). Nalbuphine is a kappa-opioid receptor agonist that can provide analgesia with fewer side effects than other opioid analgesics. This study aimed to evaluate pain control, side effects, and neonatal outcomes from combining nalbuphine with sufentanil and ropivacaine in 600 women during epidural anesthesia while giving birth at a high altitude in Xining, China. A total of 600 parturients receiving epidural labor analgesia were randomly divided into 2 groups, each group 300 parturients. The nalbuphine group received nalbuphine, sufentanil, and ropivacain, the control group only received sufentanil and ropivacain. The analgesic effect was evaluated through the Visual Analogue Scale scores. Neonatal outcomes were mainly evaluated through the Apgar Scores. Compared to the control group, the nalbuphine group showed lower Visual Analogue Scale scores at all time points after analgesia (P < .05). In comparison with the control group, parturients in the nalbuphine group showed lower incidence rates of fever at delivery, 24-hour postpartum bleeding, and pruritus (P < .05). However, between the 2 groups, there were no statistically significant differences in the remaining maternal and infant outcomes and neonatal outcomes (P > .05). Moreover, no adverse effects on neonatal outcomes were observed. The findings from this study support findings from previous studies that nalbuphine provided safe epidural analgesia without significant side effects for the mother and infant, and showed both safety and efficacy when used during labor at high altitude.
FIELD: medicine. SUBSTANCE: method involves taking liquid sample from the first patient. It is united with antibody showing specific immunoreactivity with ICAM- 4. Quantitative analysis of ICAM-4/antibody binding is carried out in the sample. ICAM/antibody binding is compared in the sample to the like binding in the sample taken from the second patient having no neurologic disease. Cleaned and separated DNA contains promoting agent for ICAM-4 mammalians. Chimera polynucleotide has promoting agent for human ICAM-4 gene. Expression vector contains the mentioned DNA. Host cell is transformed with the expression vector. Polypeptide denoted as ICAM-4 belongs to cell adhesion factors. It possesses structural affinity to intercellular adhesion factors ICAM-1, ICAM-2, ICAM-R. EFFECT: enhanced reliability in determining levels of soluble ICAM-4. 5 cl, 5 tbl
The invention relates to a system and a method for detecting occupant disease symptoms. Systems and methods for detecting occupant disease symptoms are disclosed herein. In an embodiment, the memory is configured to maintain a visualization application and data from one or more sources, such as an audio source, an image source, and/or a radar source. The processor is in communication with the memory and the user interface. The processor is programmed to: receiving data from the one or more sources; executing a human detection model based on the received data; performing an activity recognition model that recognizes disease symptoms based on the data from the one or more sources; determining a location of the identified symptom; and executing the visualization application to display the information in the user interface. The visualization application can display a background image with an overlay image that includes an indicator for each location of the identified disease symptom. In addition, data from audio sources, image sources, and/or radar sources can be fused.
Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
Derma-Smoothe/FS® may be used twice daily for up to 4 weeks in pediatric patients 2 years and older with moderate to severe atopic dermatitis. Derma-Smoothe/FS® should not be applied to the diaper area.

Application to intertriginous areas should be avoided due to the increased possibility of local adverse events such as striae, atrophy, and telangiectasia, which may be irreversible. The smallest amount of drug needed to cover the affected areas should be applied. Long term safety in the pediatric population has not been established.

Derma-Smoothe/FS® is not recommended for use on the face (see ADVERSE REACTIONS section).

Because of a higher ratio of skin surface area to body mass, children are at a greater risk than adults of HPA-axis-suppression when they are treated with topical corticosteroids. They are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing's syndrome while on treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. (SEE PRECAUTIONS).

HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Derma-Smoothe/FS® is formulated with 48% refined peanut oil NF. Peanut oil used in this product is routinely tested for peanut proteins through amino acid analysis; the quantity of amino acids is below 0.5 parts per million (ppm). 

Physicians should use caution in prescribing Derma-Smoothe/FS® for peanut sensitive individuals.
We highlight an under-recognized epileptic pathology in a 56-year-old left-handed female with progressive right facial numbness and weekly focal seizures characterized by episodic aphasia. She was found to have a left frontoparietal intradiploic meningoencephalocele (IDME). Her only epilepsy risk factor was minor head trauma 10 years prior to presentation. She underwent craniotomy for encephalocele resection and mesh cranioplasty without residual neurological deficits and excellent seizure outcome: at 3-year follow-up, she was still seizure-free since surgery, except for an isolated breakthrough seizure at 7 postoperative months when she discontinued her preoperative regimen of Lacosamide monotherapy. Traumatic IDME is a rare condition and rarely presents with seizures. Symptoms may arise up to decades following minor head trauma and are progressive in nature. The likely definitive treatment is cranioplasty and dural repair with or without resecting the protruding parenchyma.
The invention discloses a bandage for treating congo red pyogenic carbuncle of buttocks. The bandage comprises a bandage body (1). The four corners of the bandage body (1) are each provided with a tie belt (4). A cataplasm (2) for sticking medicine is arranged on the cloth face of the bandage body (1). The four edges of the cataplasm (2) are each provided with a piece of preset paper (3) for containing medicine mud blocks conveniently. Frame strips of the cataplasm with no preset paper (3) can be used for being stuck to skin, wherein a medicine mud block formed by mashing rhizoma arisaematis, Scutellaria indica, Pellionia scabra Benth., Longhairy Antenoron Herb, Viola diffusa Ging. fructus polygoni orientalis on the basis of the ratio being 5:2:2:1:1:1:1 is arranged on the cataplasm (2). When the bandage is in use, the medicine mud blocks together with leaves of Japanese bananas are stuck to the cataplasm (2), and finally the frame strips of the cataplasm on the bandage body (1) are used for sticking skin and the tie belts (4) are used for fixing the body. The bandage has the advantages of being proper in external application fixation, low in cost, capable of taking effect rapidly and good in effect.
Patients enrolled in the study will receive sevoflurane 6% for induction of general anesthesia followed by rocuronium 0.6 mg/kg to facilitate tracheal intubation. In patients allocated to the Miller group, the POGO and C\&L classification will be recorded using video laryngoscopy with a Miller blade followed by an assessment using the Cobalt blade. Intubation will then be attempted during the second assessment. Endotracheal tube size will be selected according to body weight and a guiding stylet will be used. If the first attempt at intubation fails, the subsequent attempts will be left at the discretion of the attending anesthesiologist.
Group-A human rotavirus (HRV) is one of the most common pathogenies giving rise to severe diarrhea of infants and is epidemic around the world, and about 90% of infants no matter in the developed countries or the developing countries in the world are infected by the HRV before three years old. At present, the popular human rotavirus strains in the world are mainly serotypes G1, G2, G3 and G9. G5-type human rotavirus is obtained from swine excrements through separation at first, and subsequently is detected out in Brazil, Argentina and other places. Therefore, making further researches of the G5 rotavirus on whether the further evolved G5 rotavirus is more unsuitable for infecting humans and becomes a predominant strain of the human rotavirus, and particularly, whether the epidemic rule of the rotavirus changes after rotavirus vaccines are inoculated on large scale becomes essential. A complete sequence of the rotavirus is obtained by means of an RT-PCR (Reverse Transcription-Polymerase Chain Reaction) technology. An MA104 cell is utilized to culture the rotavirus, an electron microscope picture on the cytopathogenic effect of the rotavirus is obtained, and the virulence of the rotavirus is determined by using a semilogarithm dilution method.
PROBLEM TO BE SOLVED: To obtain an inhibitor having an acyl coenzyme-A cholesterol acyl transferase activity(ACAT) inhibiting action and useful for curing or prevention of arterial atheroma or unbalancing of lipid of skin, etc. SOLUTION: The objective activity inhibitor is preferably composed of essence of a plant in any of Ligustrum pulpurasence or Ligustrum pedoncrale belonging to genus Ligustrum in family Oleaceae. Preferably, a using position of the essence is a leaf part and the essence is an extract from a polar solvent. An optimum one in the essence is obtained by extracting a leaf part with hot water, adsorbing to a suitable carrier, eluting with ethanol and condensing under a reduced pressure. The inhibitor is administrated to a human of hyperlipemia, arteriosclerosis, etc. or coated on a skin containing excess fats, etc., as a food or a medicinal composition.
PURPOSE:To obtain hair tonic having remedying effect, by mixing the ethanol decomposition liquid of decocted HIJIKI (Hizikia fusiforme, a kind of brown algae) and KUROME (Ecklonia kurome, a kind of brown algae), the ethanol extraction liquid of OBAKU (bark of Phellodendron amurense, a tree belonging to Rutaceae family), peppermint, sesame, ginger and Guinea pepper, glycerol, and sap of gourd. CONSTITUTION:For example, 70g of HIJIKI and 80g of KUROME are decocted with boiling water, and decomposed with ethanol. Separately, 25g of OBAKU, 100g of sesame, 200g of peppermint, 35g of ginger and 30g of Guinea pepper are extracted with 1 liter of ethanol. The objective hair tonic is obtained by mixing 1pt. of the extract with the above decocted liquid, 1pt. of the sap of gourd and 1pt. of glycerol. the hair tonic prevents the drying of scalp and hair by the viscous property of the glycerol, improves the metabolism and blood circulation by the motor centerstimulating effect of ginger and Guinea pepper, promotes the growth of hair by the dark pigment of HIJIKI and KUROME and chlorophyll in the peppermint, and exhibits remedying effect to external wound.
Differential physical therapy treatment, based on assessment results, with follow-up visits for PT treatment 1 - 2 times per week until patient achieves at least 1 primary outcome. They will pragmatically design an individualized and progressive treatment plan, including manual therapy (manipulation and/or mobilization), neuromotor control strategies, and vestibular rehabilitation techniques, depending on the findings at assessment and patient response. Therapists can also tailor education regarding mental and physical rest according to specific parameters provided by the treating physician. Patients may also be prescribed a home exercise program and exercise education. The precise treatment strategies will be recorded.
TAK-659 tablet, orally, once daily along with venetoclax tablet, orally, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant. TAK-659 and venetoclax MTD/RP2D will be determined from the dose escalation phase.